John Jefferies
About John Jefferies
John L. Jefferies, M.D., M.B.A., M.P.H., is Chief Medical Officer (CMO) of Daxor Corporation; he was appointed on June 5, 2024 and is listed as serving since 2025, age 55 . He is a board‑certified cardiologist with adult cardiovascular training at the Texas Heart Institute and pediatric cardiology training at Texas Children’s Hospital (Baylor College of Medicine), and holds an M.P.H. (University of Kentucky) and an M.B.A. (Wharton) . Jefferies has published over 300 peer‑reviewed manuscripts, is Editor of two leading cardiovascular textbooks, and remains actively involved in clinical research and physician leadership at local, national, and international levels . Company performance metrics (TSR, revenue, EBITDA) tied to his tenure are not disclosed in company documents; his recent remarks emphasize broadening clinical adoption and market penetration for Blood Volume Analysis (BVA) technology .
Past Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| Texas Heart Institute | Adult Cardiovascular Diseases training | Not disclosed | Advanced clinical training foundational to cardiology leadership |
| Texas Children's Hospital (Baylor College of Medicine) | Pediatric Cardiology training | Not disclosed | Specialized pediatric cardiology expertise enhancing breadth of clinical perspective |
| Academic cardiology (various institutions) | Academic cardiologist, researcher | Over two decades | Extensive peer‑reviewed output (>300 manuscripts) and leadership supporting evidence‑based adoption |
External Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| Cardiovascular textbooks (publisher not disclosed) | Editor (two leading textbooks) | Not disclosed | Thought leadership shaping clinical practice standards |
| Clinical research and physician leadership (local, national, international) | Physician leader | Not disclosed | Influence across professional communities aiding clinical adoption of BVA |
Fixed Compensation
| Metric | FY 2024 |
|---|---|
| Base Salary (USD) | $160,000 |
| Company 401(k) Match / Expenses (USD) | $614 |
| Pension or Retirement Accrual | None |
| Total Cash Compensation (USD) | $160,614 |
Notes: Officers serve annual terms and are elected annually; the company is a controlled company under Nasdaq rules and has no standing compensation committee—the full Board considers compensation .
Performance Compensation
Stock Options
| Title | Date Exercisable / Vesting | Expiration Date | Underlying Shares | Exercise Price | Ownership Form |
|---|---|---|---|---|---|
| Stock Options (right to buy) | Presently exercisable in full (1) | 04/30/2028 | 885 | $11.30 | Direct |
| Stock Options (right to buy) | Three equal installments on 12/01/2023, 12/01/2024, 12/01/2025 (2) | 12/01/2027 | 14,660 | $9.55 | Direct |
| Stock Options (right to buy) | Presently exercisable in full (1) | 11/30/2027 | 539 | $9.51 | Direct |
| Stock Options (right to buy) | Presently exercisable in full (1) | 10/31/2027 | 283 | $13.25 | Direct |
| Stock Options (right to buy) | Presently exercisable in full (1) | 09/30/2027 | 236 | $13.25 | Direct |
| Stock Options (right to buy) | Presently exercisable in full (1) | 08/31/2027 | 309 | $13.74 | Direct |
| Stock Options (right to buy) | Presently exercisable in full (1) | 07/31/2027 | 448 | $13.96 | Direct |
| Stock Options (right to buy) | Presently exercisable in full (1) | 06/30/2027 | 284 | $13.20 | Direct |
| Stock Options (right to buy) | Presently exercisable in full (1) | 05/31/2027 | 406 | $12.63 | Direct |
| Stock Options (right to buy) | Presently exercisable in full (1) | 04/30/2027 | 327 | $11.48 | Direct |
| Stock Options (right to buy) | Presently exercisable in full (1) | 03/31/2027 | 364 | $10.65 | Direct |
| Stock Options (right to buy) | Presently exercisable in full (1) | 02/28/2027 | 469 | $10.65 | Direct |
| Stock Options (right to buy) | Presently exercisable in full (1) | 01/31/2027 | 380 | $10.53 | Direct |
| Stock Options (right to buy) | Presently exercisable in full (1) | 12/31/2026 | 199 | $11.29 | Direct |
| Stock Options (right to buy) | Presently exercisable in full (1) | 11/30/2026 | 216 | $11.00 | Direct |
| Stock Options (right to buy) | Presently exercisable in full (1) | 10/31/2026 | 116 | $10.81 | Direct |
| Stock Options (right to buy) | Presently exercisable in full (1) | 09/30/2026 | 353 | $11.68 | Direct |
| Stock Options (right to buy) | Presently exercisable in full (1) | 08/31/2026 | 221 | $9.60 | Direct |
| Stock Options (right to buy) | Presently exercisable in full (1) | 07/31/2026 | 275 | $9.09 | Direct |
| Stock Options (right to buy) | Presently exercisable in full (1) | 06/30/2026 | 224 | $10.60 | Direct |
| Stock Options (right to buy) | Presently exercisable in full (1) | 05/31/2026 | 147 | $9.35 | Direct |
| Stock Options (right to buy) | Presently exercisable in full (1) | 04/30/2026 | 129 | $9.72 | Direct |
| Stock Options (right to buy) | Presently exercisable in full (1) | 03/31/2026 | 145 | $12.10 | Direct |
Vesting explanation per Form 3: “(1) This option is presently exercisable in full.” “(2) The stock options will vest in three equal installments on December 1, 2023, December 1, 2024 and December 1, 2025.”
RSUs/PSUs and Cash Bonuses
- No RSU/PSU grants or cash bonuses for Dr. Jefferies are disclosed in the latest proxy’s stock grant section; that section lists grants for other officers but not for the CMO .
Performance Metrics Tied to Pay
- No explicit revenue, EBITDA, TSR, or ESG metrics linked to Jefferies’s compensation are disclosed in the proxy .
Equity Ownership & Alignment
| As-of Date | Security | Amount Beneficially Owned | Ownership Form | Percent of Common Stock |
|---|---|---|---|---|
| 2025 proxy record date | Common Stock | 21,615 | Direct | <1% (indicated by “*”) |
| 09/30/2025 (Form 3 filed 10/02/2025) | Common Stock | 15,272 | Direct | Not disclosed on Form 3 |
- Options: See detailed table above; some are presently exercisable and one large grant (14,660 shares) vests 1/3 on 12/01/2023, 12/01/2024, 12/01/2025 .
- Shares pledged as collateral: No disclosure found in company documents searched .
- Ownership guidelines and compliance status: Not disclosed in proxy .
Employment Terms
| Item | Disclosure |
|---|---|
| Position | Chief Medical Officer |
| Appointment Date | June 5, 2024 |
| Listed “Length of Time Served” | Since 2025 |
| Age | 55 |
| Term Length | Indefinite (officer), officers serve annual terms and are elected annually |
| Non‑compete / Non‑solicit | Not disclosed |
| Severance / Change‑of‑Control | Not disclosed |
| Clawbacks / Tax gross‑ups | Not disclosed |
Performance & Track Record
- Strategic adoption and market expansion: Jefferies highlighted significant growth across clinical disciplines, expansion into community hospital systems, and broadening provider relationships (cardiology subspecialties, nephrology, ICU/critical care, etc.), underscoring real‑world data generation and accelerating practice change .
- Product/market positioning: As CMO, Jefferies emphasized clinical validation (e.g., zero unplanned readmissions for optimally managed patients at HFSA) and the commercial opportunity of a multi‑billion‑dollar market for BVA .
- Next‑generation BVA launch: Upon FDA clearance of the rapid, compact, hand‑held BVA device, Jefferies highlighted accuracy, speed, and clinical precision using tracer dilution methods to overcome traditional assessment inaccuracies .
- Evidence base reinforcement: Press releases citing Duke/ACC research reflect Jefferies’s messaging on BVA’s role in euvolemia, reduced readmissions/mortality, and improved outcomes .
Compensation Committee Analysis
- Controlled company governance: Daxor qualifies as a “controlled company” under Nasdaq rules due to the Estate of Joseph Feldschuh controlling >50% voting power; as a result, the company does not have a standing compensation committee, and the full Board participates directly in compensation consideration .
- Audit committee independence: The Board determined audit committee members meet additional independence standards; Edward Feuer is an SEC‑defined “audit committee financial expert” .
Investment Implications
- Alignment and retention: Jefferies’s low cash base ($160k) alongside a layered option package—partly presently exercisable and a key grant vesting through 12/01/2025—suggests equity‑linked incentives to drive clinical adoption and commercialization; monitoring activity around vesting dates is warranted for potential trading signals .
- Ownership scale: Beneficial ownership is <1% of common stock, reducing direct financial alignment versus larger holders; however, option exposure provides upside‑linked motivation .
- Governance risk: Absence of a dedicated compensation committee and controlled company status concentrate decision‑making—investors should weigh governance flexibility against minority protection norms .
- Execution focus: Jefferies’s background and messaging center on expanding multidisciplinary clinical use and evidence generation; continued validation and speed/accuracy from next‑gen BVA may support sales momentum, but disclosures do not tie specific performance metrics to CMO pay—suggesting qualitative performance assessment rather than formulaic KPI‑based incentives .
Sources: Appointment/biography and qualifications ; compensation and governance (proxy) ; beneficial ownership (proxy and Form 3) ; options detail/vesting (Form 3) ; performance/adoption commentary and clinical evidence messaging .